Development and Validation of the Scale of Psychological Adaptation for Spinal Cord Injury

Author(s):  
Jae Hyun Park ◽  
Kyong Ryoul Hwang
2021 ◽  
pp. 154596832110338
Author(s):  
Linda A. T. Jones ◽  
Chih-Ying Li ◽  
David Weitzenkamp ◽  
John Steeves ◽  
Susie Charlifue ◽  
...  

Background. In spinal cord injury, there are multiple databases containing information on functional recovery, but data cannot be pooled or compared due to differences in how function is measured. A crosswalk is needed to link or convert scores between instruments. Objectives. To create a crosswalk between the voluntary musculoskeletal movement items in the Functional Independence Measure (FIM®) and the Spinal Cord Independence Measure III (SCIM III) for spinal cord injury. Methods. Retrospective datasets with FIM® and SCIM III on the same people were used to develop (Swiss dataset, n = 662) and validate (US, n = 119, and Canadian datasets, n = 133) the crosswalks. Three different crosswalk methods (expert panel, equipercentile, and Rasch analysis) were employed. We used the correlation between observed scores on FIM® and SCIM III to crosswalked scores as the primary criterion to assess the strength of the crosswalk. Secondary criteria such as score distributions, Cohen’s effect size, point differences, and subgroup invariance were also evaluated. Results. All three methods resulted in strong correlation coefficients, exceeding the primary criterion value of r = .866 (.897–.972). Assessment of secondary criteria suggests the equipercentile and Rasch methods produced the strongest crosswalks. Conclusions. The Rasch FIM®/SCIM III crosswalk is recommended because it is based on co-calibration of linearized measures, allowing for more sophisticated parametric analyses. The crosswalk will allow comparisons of voluntary musculoskeletal functional recovery across international databases using different functional measures, as well as different systems of care and rehabilitation approaches.


2017 ◽  
Vol 98 (10) ◽  
pp. e50-e51
Author(s):  
Kerri Morgan ◽  
Kelly Taylor ◽  
Susan Tucker ◽  
W. Todd Cade ◽  
Joseph Klaesner

Spinal Cord ◽  
2017 ◽  
Vol 55 (11) ◽  
pp. 1010-1015 ◽  
Author(s):  
N Liu ◽  
H Xing ◽  
M-W Zhou ◽  
F Biering-Sørensen

Spinal Cord ◽  
2015 ◽  
Vol 54 (3) ◽  
pp. 197-203 ◽  
Author(s):  
K Walden ◽  
L M Bélanger ◽  
F Biering-Sørensen ◽  
S P Burns ◽  
E Echeverria ◽  
...  

2014 ◽  
Vol 155 (39) ◽  
pp. 1549-1557 ◽  
Author(s):  
Amanda Zsoldos ◽  
Ágnes Sátori ◽  
Ágnes Zana

Introduction: The animal-assisted programs represent an interdisciplinary approach. They can be integrated into preventive, therapeutic and rehabilitative processes as complementary methods. Aim: The aim of the study was to promote the psychological adaptation and social reintegration of patients who suffered spinal cord injury, as well as reducing depression and feelings of isolation caused by the long hospitalization. The hypothesis of the authors was that the animal-assisted intervention method can be effectively inserted into the rehabilitation process of individuals with spinal cord injury as complementary therapy. Methods: 15 adults with spinal cord injury participated in the five-week program, twice a week. Participants first filled out a questionnaire on socio-demographics, and after completion of the program they participated in a short, directed interview with open questions. During the field-work, after observing the participants, qualitative data analysis was performed. Results: The results suggest that the therapeutic animal induced a positive effect on the emotional state of the patients. Participants acquired new skills and knowledge, socialization and group cohesion had been improved. Conclusions: The authors conclude that the animal-assisted activity complemented by therapeutic elements can be beneficial in patients undergoing spinal cord injury rehabilitation and that knowledge obtained from the study can be helpful in the development of a future animal-assisted therapy program for spinal cord injury patients. Orv. Hetil., 2014, 155(39), 1549–1557.


Spinal Cord ◽  
2019 ◽  
Vol 57 (12) ◽  
pp. 1064-1075
Author(s):  
Anja M. Raab ◽  
Sonja de Groot ◽  
David J. Berlowitz ◽  
Marcel W. M. Post ◽  
Jacinthe Adriaansen ◽  
...  

2020 ◽  
Vol 101 (3) ◽  
pp. 401-411
Author(s):  
Mayra Galvis Aparicio ◽  
Valerie Carrard ◽  
Davide Morselli ◽  
Marcel W.M. Post ◽  
Claudio Peter ◽  
...  

2012 ◽  
Vol 17 (Suppl1) ◽  
pp. 157-229 ◽  
Author(s):  
Charles H. Tator ◽  
Robin Hashimoto ◽  
Annie Raich ◽  
Daniel Norvell ◽  
Michael G. Fehlings ◽  
...  

There is a need to enhance the pipeline of discovery and evaluation of neuroprotective pharmacological agents for patients with spinal cord injury (SCI). Although much effort and money has been expended on discovering effective agents for acute and subacute SCI, no agents that produce major benefit have been proven to date. The deficiencies of all aspects of the pipeline, including the basic science input and the clinical testing output, require examination to determine remedial strategies. Where has the neuroprotective/pharmacotherapy preclinical process failed and what needs to be done to achieve success? These are the questions raised in the present review, which has 2 objectives: 1) identification of articles that address issues related to the translational readiness of preclinical SCI pharmacological therapies; and 2) examination of the preclinical studies of 5 selected agents evaluated in animal models of SCI (including blunt force trauma, penetrating trauma, or ischemia). The 5 agents were riluzole, glyburide, magnesium sulfate, nimodipine, and minocycline, and these were selected because of their promise of translational readiness as determined by the North American Clinical Trials Network Consortium. The authors found that there are major deficiencies in the effort that has been extended to coordinate and conduct preclinical neuroprotection/pharmacotherapy trials in the SCI field. Apart from a few notable exceptions such as the NIH effort to replicate promising strategies, this field has been poorly coordinated. Only a small number of articles have even attempted an overall evaluation of the neuroprotective/pharmacotherapy agents used in preclinical SCI trials. There is no consensus about how to select the agents for translation to humans on the basis of their preclinical performance and according to agreed-upon preclinical performance criteria. In the absence of such a system and to select the next agent for translation, the Consortium has developed a Treatment Strategy Selection Committee, and this committee selected the most promising 5 agents for potential translation. The results show that the preclinical work on these 5 agents has left numerous gaps in knowledge about their preclinical performance and confirm the need for significant changes in preclinical neuroprotection/pharmacotherapy trials in SCI. A recommendation is made for the development and validation of a preclinical scoring system involving worldwide experts in preclinical and clinical SCI.


Sign in / Sign up

Export Citation Format

Share Document